Dr. Lucca Richeldi:Nos presenta Lo más nuevo en el tratamiento y pronóstico de FPI en #ADEN 2019 Se inició a combinar los dos antifibróticos disponibles en FPI demostrando al menos ser seguros INJOURNEY Trial👉https://t.co/ulPM8BBqg0 ECC de Dr Richeldi👉http
RT @leticiakawano: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis: high drop out rates... a larger s…
Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis: high drop out rates... a larger study is necessary, but how feasible would it be? Especially with so many other drugs in the pipeline #pulmonaryfibrosis #IPF https://t.c
RT @respandsleepjc: #rsjc now will be moving on to Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOU…
#rsjc now will be moving on to Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial https://t.co/VJugRT6oOn @twhcmr @shapps999 @breathewheezy
RT @respandsleepjc: Join us tonight #rsjc https://t.co/eHkqIzirA6
Join us tonight #rsjc https://t.co/eHkqIzirA6
“Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.” https://t.co/pL8deWixdg https://t.co/VEb1BtlwSz
RT @NitinSeam: Look forward to taping a podcast for Out of the Blue on this important article. https://t.co/C39pRTGsHD
Article 2: #rsjc Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial https://t.co/YUGPHWZhVw
Look forward to taping a podcast for Out of the Blue on this important article. https://t.co/C39pRTGsHD
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @ild_inn: Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial | American Journal of Resp…
RT @ild_inn: Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial | American Journal of Resp…
RT @ild_inn: Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial | American Journal of Resp…
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial | American Journal of Respiratory and Critical Care Medicine https://t.co/G4crCGnL6E
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @tipssovetorax: Fibrosis Pulmonar Idiopatica: Nintedanib+Pifenidona.. es mejor? que tan seguro? @hermes2121 @betuliochacin @benitorh @DC…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @gburgeILDNN: Nintedamib & add on Pirfenidone INJOURNEY 12 week study confirm manageable side effects and need for further study @ild_i…
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/FsOX3Q7rOk @atscommunity https://t.co/mpSYDGeRon
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @KaminskiMed: When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
When Pulmonary Medicine follows oncology - combination therapy for Idiopathic Pulmonary Fibrosis ? https://t.co/ioSNK9Wkhf
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
RT @ATSBlueEditor: Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommun…
Nintedanib with Add-on Pirfenidone is Safe and Tolerable in #IPF. The INJOURNEY Trial https://t.co/XSglfl4aGr @atscommunity https://t.co/zQfhwpaun5
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
TERAPIA COMBINADA PARA FPI Un ensayo clínico utilizando NINTEDANIB + PIRFENIDONA por 12 semanas (ambas drogas... https://t.co/fSjLjc4RGp
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @gburgeILDNN: Will combination therapy of Pirfenidone and Nintedamib result in dose reduction @ild_inn https://t.co/NoNOJFxWJ9
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
La estrategia Nintedanib + agregar Pirfenidona fue segura y más efectiva que Nintedanib solo en... https://t.co/pzVtxDOu3i
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
RT @atscommunity: Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJk…
Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial: https://t.co/0LaklJkTTu #IPF
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @gburgeILDNN: Will combination therapy of Pirfenidone and Nintedamib result in dose reduction @ild_inn https://t.co/NoNOJFxWJ9
RT @gburgeILDNN: Will combination therapy of Pirfenidone and Nintedamib result in dose reduction @ild_inn https://t.co/NoNOJFxWJ9
RT @SamirNus: Pirfenidone added to Nintedanib was tolerable. Will it allow future dose reduction? #Pulmonaryfibrosis #ERSCongress https://t…
Pirfenidona+Nintedanib parece ser seguro y más efectivo que Nintedanib solo en Fibrosis Pulmonar Idiop[atica... https://t.co/esERyTIfAH
RT @AbelPharma: Muy buenas noticias! Hoy se han publicado los datos de INJOURNEY 1r estudio que de la combinación en #FPI #ERS2017 https:/…
RT @boehringerus: #NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT…
RT @AbelPharma: Muy buenas noticias! Hoy se han publicado los datos de INJOURNEY 1r estudio que de la combinación en #FPI #ERS2017 https:/…
RT @AbelPharma: Muy buenas noticias! Hoy se han publicado los datos de INJOURNEY 1r estudio que de la combinación en #FPI #ERS2017 https:/…
RT @SamirNus: Pirfenidone added to Nintedanib was tolerable. Will it allow future dose reduction? #Pulmonaryfibrosis #ERSCongress https://t…
RT @SamirNus: Pirfenidone added to Nintedanib was tolerable. Will it allow future dose reduction? #Pulmonaryfibrosis #ERSCongress https://t…
RT @SamirNus: Pirfenidone added to Nintedanib was tolerable. Will it allow future dose reduction? #Pulmonaryfibrosis #ERSCongress https://t…
#NEWS: Results from the #INJOURNEY trial for the treatment of #IPF published in @ATSBlueJournal: https://t.co/psGE48u2aT https://t.co/o9IXFyxD7Y